GlassScriptPhysician profile
Kevin M Kapadia
NPI 1255565875
$11,162.65
in general payments reported to CMS, 2019-2025
53 companies · $4,353 in 2025
The $4,353 reported for 2025 was more than what 84% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17.75 · 2020: $41.94 · 2021: $793 · 2022: $1,688 · 2023: $1,759 · 2024: $2,510 · 2025: $4,353.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,594 · Education: $28.63.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,593.87 |
| Education | $28.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,200.23 | 2021-2025 | |
| Pfizer INC. | $669.64 | 2023-2025 | |
| Ucb, INC. | $635.19 | 2021-2025 | Rystiggo, Fintepla, Briviact |
| Biogen, INC. | $537.98 | 2021-2025 | Vumerity |
| Novartis Pharmaceuticals Corporation | $505.19 | 2021-2025 | |
| Genzyme Corporation | $367.72 | 2021-2022 | |
| Eisai INC. | $340.42 | 2021-2025 | |
| Sk Life Science, INC. | $300.94 | 2023-2025 | |
| Lundbeck LLC | $297.43 | 2021-2025 | Vyepti |
| Tg Therapeutics, INC. | $292.39 | 2024-2025 | |
| Amgen INC. | $258.86 | 2021-2025 | Uplizna |
| Lilly USA, LLC | $254.90 | 2022-2025 | Kisunla, Emgality, Reyvow |
| Allergan, INC. | $241.02 | 2020-2022 | |
| Argenx US, INC. | $239.59 | 2024-2025 | Vyvgart Hytrulo |
| Teva Pharmaceuticals USA, INC. | $228.55 | 2023-2025 | Austedo Xr, Austedo, Austedo Xr |
Show all 53 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $200.22 | 2021-2025 | Mavenclad |
| Csl Behring | $198.76 | 2022-2025 | Hizentra |
| Jazz Pharmaceuticals INC. | $170.32 | 2023-2025 | |
| Genentech USA, INC. | $163.74 | 2021-2025 | Ocrevus Zunovo, Ocrevus |
| Alexion Pharmaceuticals, INC. | $142.09 | 2020-2025 | Ultomiris |
| Amneal Pharmaceuticals LLC | $140.12 | 2023-2025 | Crexont, Rytary |
| Neurelis, INC. | $135.68 | 2022-2025 | Valtoco |
| Acadia Pharmaceuticals INC | $134.98 | 2024-2025 | Nuplazid |
| Tanabe Pharma America, INC. | $128.86 | 2023-2025 | Radicava |
| Vanda Pharmaceuticals INC. | $128.85 | 2024-2025 | Ponvory |
| Biohaven Pharmaceutical Holding Company LTD. | $128.72 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $119.87 | 2024-2025 | Hyqvia |
| Inspire Medical Systems, INC. | $98.24 | 2023-2024 | Inspire |
| Grifols USA, LLC | $85.66 | 2024-2025 | Gamunex-C |
| Harmony Biosciences LLC | $68.52 | 2022 | |
| Merz Pharmaceuticals, LLC | $66.55 | 2024-2025 | Xeomin, Ampyra, Inbrija |
| Octapharma USA, INC. | $65.53 | 2024-2025 | Panzyga |
| Cala Health, INC. | $55.74 | 2025 | Cala Kiq |
| Celgene Corporation | $46.26 | 2021-2024 | Zeposia |
| Neuropace, INC. | $46.22 | 2024 | |
| Averitas Pharma INC. | $44.45 | 2024-2025 | Qutenza |
| Livanova USA, INC. | $42.98 | 2022-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Otsuka America Pharmaceutical, INC. | $42.28 | 2023 | Nuedexta |
| Sumitomo Pharma America, INC. | $40.98 | 2023 | Aptiom |
| Microtransponder, INC. | $30.59 | 2024 | |
| Acorda Therapeutics, INC | $26.04 | 2022 | |
| Mdd US Operations, LLC | $25.17 | 2023 | Apokyn |
| Impel Pharmaceuticals INC. | $24.98 | 2023 | Trudhesa |
| Banner Life Sciences, LLC | $23.80 | 2021 | |
| Impel Pharmaceuticals LLC | $22.99 | 2024 | Trudhesa |
| Adamas Pharmaceuticals, INC. | $21.28 | 2021 | |
| Alnylam Pharmaceuticals INC. | $20.43 | 2024 | Onpattro |
| Janssen Biotech, INC. | $19.51 | 2025 | |
| Saol Therapeutics INC. | $17.75 | 2019 | |
| Mallinckrodt Hospital Products INC. | $17.74 | 2024 | Acthar |
| Amylyx Pharmaceuticals, INC. | $17.00 | 2023 | Relyvrio |
| Upsher-Smith Laboratories LLC | $15.37 | 2023 | |
| Scilex Pharmaceuticals INC. | $14.33 | 2023 | Ztlido |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Kapadia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.